The Pennsylvania Supreme Court has ruled that the start date of the statute of limitations for bringing products liability claims over antipsychotic drug Risperdal must be determined by a jury following a factual analysis in each individual case.
In identical 6-1 decisions issued Nov. 20 in Saksek v. Janssen and Winter v. Janssen, the justices overturned a Superior Court ruling that granted summary judgment to Johnson & Johnson subsidiary Janssen and tossed out lawsuits filed by plaintiffs Jonathan Saksek and Joshua Winter—and, by extension, thousands of other plaintiffs—who alleged they developed excess breast tissue as a result of taking Risperdal.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]